Covid Researchers Work Round the Clock to Solve Pandemic

Share Article

Clinical research sites formed networks across the country prior to COVID-19. It's almost as if the industry was unknowingly preparing itself to handle a major pandemic. Platinum Research Network has initiated over 30 clinical research sites to vaccine trials and enrolled over 6,000+ patients. Support, training, and quality assurance teams have grown by 75-90% since the spring. The industry is clearly moving significantly faster than usual. Pediatric and older adults will be the next population to enter several rounds of studies. Jason Roth and network physicians are available for interview via various platforms and can provide more information about their vaccine efforts.

Platinum Research Network

Platinum Research Network has grown by 60% since COVID-19 hit, enrolled over 6k patients, and is prepared for the next round of Pediatric and older adult populations to begin clinical trials.

In these unpredictable times, not all clinical research site networks are created equal. Platinum Research Network's physicians have been on the forefront of groundbreaking work. The current pandemic is no exception. Many research companies unite to form a network of research centers. This allows for a more efficient process. It's almost as if the industry was unknowingly preparing itself to handle a major pandemic. 

A previous medical officer in the Army National Guard, Dr. Robert Jeanfreau recently worked with medics in the National Guard to set up local testing units in their New Orleans community, which was hit early-on in the pandemic. Since then Dr. Jeanfreau has initiated a dozen clinical trials exploring new treatments and vaccines for COVID-19. "The researchers are the ones that are really going to win this thing, and we have to support them to the best of our ability," Jeanfreau said. "We have no official treatment, and in order to get that, we must let these guys do their work. We have the best scientists in the world. I have no doubt that they are going to come up with some really good answers, but we have to help them. This is how we do it."

Jason Roth, of Platinum Research Network states, “Our clinical teams have been supporting vaccine projects since early summer and started planning earlier in the spring.” To date, PRN has initiated over 30 clinical research sites to vaccine trials and has enrolled over 7,000+ patients as of September 17th. This number is predicted to grow by 1000+ patients per week." The industry is clearly moving significantly faster than usual. “On average, our clinical support, training, and quality assurance teams have grown by 75-90% since the spring." That number is no doubt astounding.

As trials continue to meet safety and efficacy milestones in healthy adult populations, inevitably these vaccines, treatments and preventatives will need to be tested in patients traditionally considered to be "at risk". Pediatric and older adults will be the next population to enter several rounds of studies. At least 1/3 of the vaccine research PRN conducts is with pediatrics. Their teams are geared up to support COVID-19 vaccine trials in this younger age group later in the year. 

-Jason Roth and network physicians are available for interview via various platforms and can provide more information about their vaccine efforts. They are happy to share details about their full capabilities. PRN states they are ready to keep partnering with the industry and help get a viable vaccine approved sooner than later.

Contact: Jason Roth Jason.Roth@platinum-research.net
Phone: 512.797.0030

*About Platinum Research Network: PRN is a vaccine-specialized Investigator network providing access to a geographic spread of highly-experience clinical research teams in the United States. To date, PRN investigators have initiated over 500 vaccine projects at their sites, enrolling over 35,000 patients at rate of 110% per our contact goals. They truly excel at delivering high quality data and predictable enrollment for vaccine studies.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lauren Foreman

Jason Roth
Visit website